By Sean Orr, M.D. | October 9, 2026 | Florida Doctor Magazine
A fifty-two-year-old patient comes to a Sarasota office with a rotator cuff tear that has been slow to heal and a small vial that he ordered online. The label says BPC-157 and “for research use only,” and he would like his physician either to supervise the injections or to prescribe the same peptide from a pharmacy. For the last three years the physician could answer that no pharmacy was authorized to compound it. That answer may be about to change, although no new evidence would come with the change.
On October 7, The Washington Post reported, citing two people familiar with the plan, that the Trump administration is preparing a temporary measure that would allow some previously restricted peptides to be sold through compounding pharmacies while federal officials write new regulations. The plan has not been announced, and the Post noted that its timing could change. Florida physicians should decide now what they will do if the policy is announced.
What Was Reported This Week
According to the Post’s account, as summarized by Becker’s Hospital Review on October 8, some compounding pharmacies would be permitted to dispense certain peptides during the interim period, subject to conditions that officials are still discussing. The Alliance for Pharmacy Compounding has asked the Food and Drug Administration for interim enforcement discretion for state-licensed pharmacies, with three conditions: enhanced disclosures to patients, reporting of serious adverse events, and collection of data on how the peptides are used.
The reports did not name the peptides. The likely candidates are the seven that the FDA’s Pharmacy Compounding Advisory Committee reviewed on July 23 and 24: BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, and Epitalon. The committee recommended all of them except emideltide for the list of substances that pharmacies may compound. The vote on BPC-157 was 8 to 6 with one abstention, according to ABC News.
Where the Law Stands Today
Section 503A of the Federal Food, Drug, and Cosmetic Act allows a pharmacy to compound a drug for an identified patient on a valid prescription, but only from a bulk substance that has a United States Pharmacopeia monograph, is a component of an FDA-approved drug, or appears on a list the agency has established by regulation. None of the seven peptides meets any of those three tests.
Until this spring the FDA kept twelve peptides, BPC-157 among them, in the category it uses for nominated substances that it believes present safety risks. On April 15, 2026, the agency announced that it would remove them from that category. Attorneys at Orrick wrote at the time that the peptides would remain in “a regulatory gray area,” because the removal did not authorize anyone to compound them.
The advisory committee’s vote did not change that. Holland & Knight’s analysis states that the recommendations are nonbinding and “did not result in any change in law,” and Sheppard Mullin has estimated that the required rulemaking could take 12 to 24 months or longer. Enforcement discretion would cover that interval. It would mean that the FDA declines to act against pharmacies that meet its conditions. It would not be a finding that the peptides are safe or effective.
The Case for Access and the Case Against It
Each side of this debate has an argument that deserves to be stated in full. FDA staff scientists told the committee that there is a general lack of quality data on the safety and effectiveness of these substances, and ABC News reported that most of the studies so far were done in rodents. ECRI and the Institute for Safe Medication Practices warned after the vote that the gaps in the evidence remain unresolved.
The argument for access is also an argument about safety. Patients are already using these peptides, and many of them are buying vials on what ABC News described as gray and black markets. Secretary Robert F. Kennedy Jr. has said that prohibiting these peptides has not protected consumers. The pharmacies argue that dispensing under conditions would at least allow safety problems to be identified. I think both arguments are correct. A peptide compounded by a licensed pharmacy is safer than a vial from an unregulated vendor, and neither one has been shown to work in a controlled human trial.
What a Stopgap Would Mean in a Florida Practice
Federal enforcement discretion would apply to pharmacies. The physician’s obligations come from Florida law, and they would not change. A prescription for a compounded peptide would still be a prescription for an unapproved drug, judged against the standard of care by the Board of Medicine or the Board of Osteopathic Medicine. Prescribing of that kind is within a physician’s discretion, and it carries the ordinary duties of an examination, a documented rationale, informed consent, and follow-up.
Florida has already shown how it treats therapies of this kind. In 2025 the Legislature enacted section 458.3245, which permits physicians to perform stem cell therapies that the FDA has not approved in orthopedics, wound care, and pain management. The statute requires a signed consent form stating that the therapy is not FDA-approved and describing the anticipated results, the risks, and the alternatives, and it requires a specific notice in any advertisement. I am not aware of a comparable Florida statute for peptides, and this one is the best available indication of what the state expects.
What Florida Physicians Should Do Now
- Do not change your prescribing on the basis of a news report. As of October 9, no policy has been announced. Wait for the FDA’s own document.
- Do not administer or supervise the use of a product labeled for research use, including one that the patient brings to the office. A stopgap would not cover online vendors, and you could not confirm the identity, purity, or sterility of what you injected.
- If the policy is announced and you choose to prescribe, verify the pharmacy first. Confirm its Florida permit, and ask in writing whether each lot of the bulk peptide comes from an FDA-registered establishment with a valid certificate of analysis, because Section 503A requires both.
- Write a consent form now, and model it on section 458.3245. It should state that the peptide is not FDA-approved and that the human evidence is limited, and it should describe the result you anticipate, the recognized risks, and the alternatives. Remove from your advertising any claim that a peptide treats or cures a condition.
- Keep a log of every patient, dose, lot number, and outcome, and report serious adverse events to FDA MedWatch and to the dispensing pharmacy whether or not the final policy requires it.
- None of this constitutes legal advice, so before you add peptides to your practice, ask your professional liability carrier in writing whether prescribing a compounded, unapproved peptide is covered under your policy, and have a Florida health care attorney review your consent form.
The Bigger Picture
While the FDA said that no pharmacy could compound BPC-157, a physician could decline a request by pointing to the agency. If the agency steps back, the decision to prescribe will rest with the physician alone, and so will the duty to tell the patient what is known and what is not known. The useful response from our profession would be to collect the outcome data that no trial has collected through the Florida Medical Association and the specialty societies, so that the FDA’s rulemaking can rest on human experience that physicians recorded carefully.
Frequently Asked Questions
Can a Florida physician prescribe BPC-157 from a compounding pharmacy today?
As of October 9, 2026, BPC-157 is not on the FDA’s list of bulk substances that pharmacies may compound under Section 503A, and no federal policy authorizing its compounding has been announced. The Washington Post reported on October 7 that a temporary measure is being prepared, but the plan has not been announced and could change.
What did the FDA advisory committee decide about peptides in July 2026?
The Pharmacy Compounding Advisory Committee met July 23 and 24, 2026, and recommended six of seven peptides for the compounding list: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. It voted against emideltide. The recommendations are nonbinding, and the FDA must complete rulemaking before the list changes.
What is FDA enforcement discretion?
Enforcement discretion means that the FDA chooses not to take action against a practice that the law does not otherwise authorize, usually under stated conditions. It does not make a compounded peptide an approved drug, and it is not a finding that the peptide is safe or effective.
Does Florida law require a special consent form for peptide therapy?
Florida has a statute, section 458.3245, that requires a signed consent form and an advertising notice for stem cell therapies that the FDA has not approved. It does not address peptides. Florida physicians who prescribe compounded peptides can use that statute as a model for consent and advertising, and the ordinary duty of informed consent applies in any case.
Should a physician administer a peptide that a patient bought online for research use?
No. A product sold for research use was not compounded by a licensed pharmacy for a patient, and the reported federal stopgap concerns compounding pharmacies only. A physician who administers such a product cannot confirm its identity, purity, or sterility.
This article was drafted with the assistance of AI writing tools, then reviewed, edited, and approved by Dr. Sean C. Orr, M.D., who holds full editorial responsibility for its content. The header illustration was created with AI image tools.
References
- The Washington Post, “Trump administration paving way for temporary sale of some unapproved peptides” (October 7, 2026). washingtonpost.com
- Becker’s Hospital Review, “HHS plans stopgap to allow sales of some unapproved peptides: Washington Post” (October 8, 2026). beckershospitalreview.com
- Alliance for Pharmacy Compounding, “Peptide plan reportedly in the works” (October 2026). a4pc.org
- ABC News, “FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list” (July 23, 2026). abcnews.com
- Holland & Knight, “FDA Advisory Committee Endorses Compounding of Certain Peptides” (August 4, 2026). hklaw.com
- Orrick, “FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings” (April 16, 2026). orrick.com
- Sheppard Mullin, “What to Watch: Status Update on Peptide Regulation” (June 15, 2026). sheppard.com
- 21 U.S.C. 353a, Pharmacy compounding (Section 503A of the Federal Food, Drug, and Cosmetic Act). law.cornell.edu
- Florida Statutes section 458.3245, Stem cell therapy. leg.state.fl.us